<DOC>
	<DOCNO>NCT00480077</DOCNO>
	<brief_summary>The DOT-HF trial international , prospective , multi-center , randomize , control trial .</brief_summary>
	<brief_title>Diagnostic Outcome Trial Heart Failure ( DOT-HF Trial )</brief_title>
	<detailed_description>The study design Control Arm order adequately study effect early intervention trigger OptiVol® Alert and/or SentryCheck™ Monitor/PatientLook™ Indicator evaluation use OptiVol® Fluid Status Monitoring Cardiac Compass . OptiVol® Fluid Status Monitoring Cardiac Compass feature available per Clinical Investigational Plan specify Medtronic product ( CRT , CRT-D ICD device )</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Subjects gender mild severe HF define NHYA Class II IV also indication device implant accord ESC/AHA guideline well HF hospitalization Emergency Department visit necessitate therapy within past 12 month meet inclusion criterion exclusion criterion , eligible study . Subject post heart transplant actively list transplant list reasonable probability ( defined investigator ) undergo transplantation next year Subject receive coronary artery bypass graft valve surgery last 90 day Subject myocardial infarction ( MI ) last 40 day . Subject 's life expectancy le one year opinion physician Subject severe Chronic Obstructive Pulmonary Disease ( COPD ) , determine physician document medical record Subject list valve replacement/valve repair Subject severe , primary pulmonary hypertension determine physician document medical record Subject serum creatinine ≥ 2.5 mg/dL measure within 14 day prior enrolment Subject chronic renal dialysis Subject continuous uninterrupted ( ≥ 2 stable infusion per week ) infusion ( inotropic ) therapy HF Subject complex uncorrected Congenital Heart Disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Heart Failure , randomize , OptiVol® Fluid status monitoring</keyword>
</DOC>